Help us to find a better treatment for atopic dermatitis
Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition characterized by intense itching (pruritus) and eczematous lesions.
Learn more about clinical trials at Novartis here
AD is a leading non-fatal health burden attributable to skin disease worldwide and can cause significant physical, psychological, and economic burden to patients, carers, and health systems alike. It is estimated to affect 5-10% of adults and 11-20% of children. Approximately 50% of patients with AD experience moderate to severe disease which requires treatment with systemic therapy. Despite advances in systemic therapies for moderate to severe AD, there remains a large unmet need for treatments that achieve high levels of skin clearance and itch relief with a safety profile suitable for long-term use. The aim of this study is to improve existing treatment options for current AD patients.
How will the study benefit me?

Access to atopic dermatitis medical care

Access to an investigational drug which may improve your condition and quality of life

The opportunity to help researchers find out more about your condition and contribute to medical knowledge that may help other people in the future